ALLUVI: A COMPREHENSIVE EXAMINATION INTO THE DRUG'S POSSIBILITIES

Alluvi, previously BI 4744, offers a notable development in obesity treatment. This dual stimulator targeting both GLP-1 and GIP sites demonstrates compelling effectiveness in clinical trials, potentially surpassing available GLP-1 receptor activators. Early findings show considerable {weight los